Advanced search
Publication Cover
Clinical Toxicology Volume 58, 2020 - Issue 11
Submit an article Journal homepage
440
Views
12
CrossRef citations to date
0
Altmetric
Poison Centre Research

Snake bites by European vipers in Mainland France in 2017–2018: comparison of two antivenoms Viperfav® and Viperatab®

David BoelsPharmacology and Toxicology Department, Nantes University Hospital, Nantes, France, and Inserm UMRS 1144, University of Paris, France; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-5599-9593
ORCID Icon,
Jean François HamelRepresentative of Clinical Research and Innovation, Angers University Hospital, Angers, France;
,
Gaël Le RouxPoison Control Centre, Angers University Hospital, Angers, France;
,
Magali LabadiePoison Control Centre, Bordeaux University Hospital, Bordeaux, France;
,
Nathalie ParetPoison Control Centre, Lyon University Hospital, Lyon, France;
,
Nicolas DelcourtPoison Control Centre, Toulouse University Hospital, Toulouse, France;
,
Jérôme LangrandPoison Control Centre, Paris University Hospital, Paris, France; ORCID Iconhttp://orcid.org/0000-0002-2123-2885
ORCID Icon,
Emmanuel PuskarczykPoison Control Centre, Nancy University Hospital, Nancy, France;
,
Patrick NissePoison Control Centre, Lille University Hospital, Lille, France;
,
Sandra Sinno-TellierANSES, French Agency for Food, Environmental and Occupational Health Safety, Maisons-Alfort, France;
&
Luc de HaroPoison Control Centre, Marseille University Hospital, Marseille, France
 show all
Pages 1050-1057 | Received 12 Dec 2019, Accepted 29 Jan 2020, Published online: 05 Mar 2020

References

  • Lamb T, de Haro L, Lonati D, et al. Antivenom for European Vipera species envenoming. Clin Toxicol. 2017;55(6):557–568.
  • Audebert F, Sorkine M, Bon C. Envenoming by viper bites in France: clinical gradation and biological quantification by ELISA. Toxicon. 1992;30(5–6):599–609.
  • Boels D, Hamel JF, Bretaudeau Deguigne M, et al. European viper envenomings: assessment of ViperfavTM and other symptomatic treatments. Clin Toxicol. 2012;50(3):189–196.
  • Berroneau M, Pottier G, Deso G. Répartition des vipères de France [Internet]. Vipères de France; [cited 2017 Nov 1]. Available from: http://vipera.fr/repartition/
  • Harry P, de Haro L, Asfar P, et al. Evaluation of intravenous immunotherapy with purified F(ab′)2 fragments (Viperfav). Presse Med. 1999;28(35):1929–1934.
  • Karlson-Stiber C, Persson H, Heath A, et al. First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Vipera berus envenoming. J Intern Med. 1997;241:53–58.
  • Karlson-Stiber C, Persson H. Antivenom treatment in Vipera berus envenoming-report of 30 cases. J Intern Med. 1994;235(1):57–61.
  • Karlson-Stiber C, Salmonson H, Persson H. A nationwide study of Vipera Berus bites during one year—epidemiology and morbidity of 231 cases. Clin Toxicol. 2006;44(1):25–30.
  • Chippaux J-P. Epidemiology of snakebites in Europe: a systematic review of the literature. Toxicon. 2012;59(1):86–99.
  • Jollivet V, Hamel JF, de Haro L, et al. European viper envenomation recorded by French poison control centers: a clinical assessment and management study. Toxicon. 2015;108:97–103.
  • Bulletin N. DGS/CORRUSS/PP1/DGOS/PF2/2017/159 of 9 May 2017 concerning the management of the shortage of antivenom serum Viperfav® during the summer season [Internet]; [cited 2018 May 1]. Available from: http://circulaire.legifrance.gouv.fr/pdf/2017/06/cir_42299.pdf
  • Casewell NR, Al-Abdulla I, Smith D, et al. Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus Antivenom ViperaTAb. Toxins (Basel). 2014;6(8):2471–2482.
  • Roecker EB. Prediction error and its estimation for subset-selected models. Technometrics. 1991;33(4):459–468.
  • Hurvich CM, Tsai C. The impact of model selection on inference in linear regression. Am Stat. 1990;44:214–217.
  • Copas JB. Regression, prediction and shrinkage. J R Stat Soc B (Methodological). 1983;45(3):311–354.
  • Smith DC, Reddi KR, Laing G, et al. An affinity purified ovine antivenom for the treatment of Vipera berus envenoming. Toxicon. 1992;30(8):865–871.
  • Rivière G, Choumet V, Audebert F, et al. Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy. J Pharmacol Exp Ther. 1997;281(1):1–8.
  • Boyer LV, Chase PB, Degan JA, et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab′)2 antivenoms. Toxicon. 2013;74:101–108.
  • Smith TW, Lloyd BL, Spicer N, et al. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. Clin Exp Immunol. 1979;36(3):384–396.
  • Gutierrez JM, Leon G, Lomonte B. Pharmacokinetic–pharmacodynamic relationships of immunoglobulin therapy for envenomation. Clin Pharmacokinet. 2003;42:721–741.
  • Brvar M, Kurtović T, Grenc D, et al. Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. Clin Toxicol. 2017;55(4):241–248.
  • Zanetti G, Duregotti E, Locatelli CA, et al. Variability in venom composition of European viper subspecies limits the cross-effectiveness of antivenoms. Sci Rep. 2018;8(1):1–9.
  • Jan V, Maroun RC, Robbe-Vincent A, et al. Toxicity evolution of Vipera aspis aspis venom: identification and molecular modeling of a novel phospholipase A2 heterodimer neurotoxin 1. FEBS Lett. 2002;527(1–3):263–268.
  • Ferquel E, de HL, Jan V, et al. Reappraisal of Vipera aspis venom neurotoxicity. PLoS One. 2007;2(11):e1194.
  • de Haro L, Glaizal M, Tichadou L, et al. Asp Viper (Vipera aspis) envenomation: experience of the Marseille Poison Centre from 1996 to 2008. Toxins. 2009;1(2):100–112.
  • Oxybel Y, Sinno-Tellier S, Hamel J-F, et al. Snake bites by European vipers in mainland France in 2017: use of two antivenoms. Presse Med. 2019;48(6):723–725.
  • de Haro L. Management of snakebites in France. Toxicon. 2012;60(4):712–718.
  • Coulson JM, Cooper G, Krishna C, et al. Snakebite enquiries to the UK National Poisons Information Service: 2004–2010. Emerg Med J. 2013;30(11):932–934.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.